Search
ACTION trial
Manufacturer-sponsored trial
Design:
- 7665 patients with stable angina
- mean age: 63.5 years
- 80% men, 98% white, 52% hypertensive
- long-acting nifedipine 60 mg QD vs placebo
- other medications as prescribed by their physicians
- 86% taking aspirin, 80% taking beta-blocker, 63% taking statin,
- 38% taking maintenance nitrates, 20% taking ACE inhibitor
Composite endpoint:
- death, myocardial infarction, refractory angina, new overt heart failure, stroke, peripheral revascularization
Results:
- mean follow-up of 5 years
- similar rates of composite endpoint & of each individual endpoint in both groups, except heart failure
- rate of new overt heart failure, coronary angiography, CABG lower in long-acting nifedipine group
Conclusions:
- long-acting nifedipine is safe for treatment of stable symptomatic angina, but is protective against new cardiovascular events
Related
nifedipine (Procardia, Adalat)
General
clinical trial
References
- Journal Watch 24(20):150, 2004
Poole-Wilson PA et al for the
A Coronary disease Trial Investigating Outcome with Nifedipine
gastrointestinal therapeutic system investigators.
Effect of long-acting nifedipine on mortality and cardiovascular
morbidity in patients with stable angina requiring treatment
(ACTION trial): randomised controlled trial.
Lancet. 2004 Sep 4;364(9437):849-57.
PMID: 15351192